In a recent announcement, Gilead Sciences ( NASDAQ:GILD ) disclosed disappointing results from a late-stage trial evaluating its antibody-drug conjugate, Trodelvy, in second-line treatment for advanced non-small cell lung cancer (NSCLC). The Phase 3 study, aiming to expand Trodelvy's applications, did not meet its primary goal of significantly improving survival...
Gilead Sciences is devoting another $200 million to its existing partnership with Arcellx the biotechnology companies said Wednesday. Kite, a Gilead (ticker: GILD) company, has exercised an option to negotiate a license for Arcellx ‘s ARC-SparX program, ACLX-001, in multiple myeloma. The companies said they also expanded the scope of their collaboration for...
I dislike trading pharma BUT I like GILD
I like this chart a lot actually. if we bounce off this crossroad, we will reach the moon eventually. Adding a little to my long position. Have a terrific weekend!
Reuters Adage Capital Partners GP LLC Dissolves Share Stake In Moderna, Takes In Gilead Sciences! Reuters: Germany requests 5% of EU supply of remdesivir Germany has requested around 5% of the supply of remdesivir under a six-month European Union supply deal, its health ministry said on Monday, despite criticism of the deal due to a lack of evidence about the...
NASDAQ:GILD Based on technical analysis, the idea is to go long only if the bottom support level of 60 USD will not be broken. Target prices are: 1. 68USD 2. 80 USD
Based on Technical Analysis the best option is to hold and wait the end of the price retracement before going long. Trump has been treated with Gilead Sciences remdesivir.
GILEAD SCIENCES, daily timeframe: Support line + Side of Bollinger bands + Nice discount + Divergence + Hammer
📍 The effect of Remdesivir... The power to unlock the all time highs via Covid is systematically, within reach rather fast, due to the nature of drug prices which are inelastic. The effect of Gilead being treated as utility is heightened by DT putting the big orders in. Compare the following two diagrams: Phase III trials & Chinese red carpet ...
Technical Analysis: HOLD BEFORE GOING LONG -Wait that the resistance level will be broken before buying. Fundamental Information: Gilead Was Approached by AstraZeneca About Potential Merger
It is trading below RSI 50 and 50SMA which put the stock in bearish. After fast dropped down, it may pull back to $75. However, if there will be no any good news will support the stock most likely it will continue descending. If you like my charts useful, please leave me "like" thx
Just Hold for now. It is too risky invest in this stock right now
Gilead WHO mistakenly posted study results that appeared to show that a leading potential coronavirus treatment failed to help patients www.businessinsider.my
U.S. FDA approved Gilead Sciences Inc.’s experimental antiviral drug, remdesivir, for use as it’s showing good signs of helping hospitalised patients recover more quickly from Corona Virus. From a Trend Analysis perspective - price action has been very choppy with lots of buying and selling in an almost Up-trending consolidation. We expect Gilead to push...
A medical tech company know for different drugs but currently it is making Remdesivir. In studies it shows it helps covid-19 recovery. Based on breaking and closing above resistance today we would go back to 110